|
Multi-Theme
Title: New Therapeutic Options in the Management of Type 2 Diabetes
Contact Hours: 4.0 (4.0 CEUs)
ACPE UPN: 161-999-07-702-H01
Expire Date: 03-10
Author: Betsy Carlisle, Pharm.D., CDE, Brackenridge Hospital, Austin, Texas
Goals & Objectives: Identify the action patterns of the newer insulins: detemir (Levemir), glulisine (Apidra) and inhaled insulin (Exubera) and their role in basal-bolus insulin regimens; understand the role of the new incretin mimetic exenatide (Byetta) in addressing insulin resistance and beta-cell dysfunction; describe the potential for pramlintide (Symlin), a synthetic amylin analogue, to complement the action of insulin by reducing glucagon secretion, affecting satiety and slowing gastrointestinal emptying.
Disclosure: The author has agreed and signed a conflict of interest statement to ensure that any information is fair and balanced. (The author does have an affiliation with Pfizer and sanofi-aventis.)
Return to course list
Course Information & Order Form (pdf)
|
